Inspira generates first revenues from deployment of INSPIRA ART100 systems

Inspira Technologies (IINN) announced that it has received payment from its U.S. distributor, Glo-Med Networks, for a delivery of its INSPIRA ART100 systems, which are cleared by the U.S. Food & Drug Administration. The revenue, in the range of the low hundreds of thousands of dollars, relates to the delivery of the INSPIRA ART100 systems, which have been recently installed at a premier U.S. academic medical center, as previously announced. In addition, additional systems are planned for installation at a second leading academic medical center. This revenue milestone represents a significant achievement in the Company’s deployment strategy, as it continues to expand its footprint in the U.S. healthcare market.